Cargando…
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
Humoral vaccine responses are known to be suboptimal in patients receiving B-cell targeted therapy, and little is known about vaccine induced T-cell immunity in these patients. In this study, we characterized humoral and cellular antigen-specific anti-SARS-CoV2 responses following COVID-19 vaccinati...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831839/ https://www.ncbi.nlm.nih.gov/pubmed/35154159 http://dx.doi.org/10.3389/fimmu.2022.834981 |
_version_ | 1784648592650141696 |
---|---|
author | Marty, Paige K. Van Keulen, Virginia P. Erskine, Courtney L. Shah, Maleeha Hummel, Amber Stachowitz, Michael Fatis, Samantha Granger, Dane Block, Matthew S. Duarte-García, Alí Warrington, Kenneth J. Theel, Elitza S. Zhou, Xian Zeng, Hu Specks, Ulrich Escalante, Patricio Peikert, Tobias |
author_facet | Marty, Paige K. Van Keulen, Virginia P. Erskine, Courtney L. Shah, Maleeha Hummel, Amber Stachowitz, Michael Fatis, Samantha Granger, Dane Block, Matthew S. Duarte-García, Alí Warrington, Kenneth J. Theel, Elitza S. Zhou, Xian Zeng, Hu Specks, Ulrich Escalante, Patricio Peikert, Tobias |
author_sort | Marty, Paige K. |
collection | PubMed |
description | Humoral vaccine responses are known to be suboptimal in patients receiving B-cell targeted therapy, and little is known about vaccine induced T-cell immunity in these patients. In this study, we characterized humoral and cellular antigen-specific anti-SARS-CoV2 responses following COVID-19 vaccination in patients with ANCA-associated vasculitis (AAV) receiving anti-CD20 therapy, who were either B-cell depleted, or B-cell recovered at the time of vaccination and in normal control subjects. SARS-CoV-2 anti-spike (S) and anti-nucleocapsid (NC) antibodies were measured using electrochemiluminescence immunoassays, while SARS-CoV-2 specific T-cell responses to S glycoprotein subunits 1 (S1) and 2 (S2) and receptor binding domain peptide pools were measured using interferon-gamma enzyme-linked immunosorbent spot (ELISPOT) assays. In total, 26 recently vaccinated subjects were studied. Despite the lack of a measurable humoral immune response, B-cell depleted patients mounted a similar vaccine induced antigen-specific T-cell response compared to B-cell recovered patients and normal controls. Our data indicate that to assure a humoral response in patients receiving anti-CD20 therapy, SARS-CoV-2 vaccination should ideally be delayed until B-cell recovery (CD-20 positive B-cells > 10/μl). Nevertheless, SARS-CoV-2 vaccination elicits robust, potentially protective cellular immune responses in these subjects. Further research to characterize the durability and protective effect of vaccine-induced anti-SARS-CoV-2 specific T-cell immunity are needed. |
format | Online Article Text |
id | pubmed-8831839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88318392022-02-12 Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy Marty, Paige K. Van Keulen, Virginia P. Erskine, Courtney L. Shah, Maleeha Hummel, Amber Stachowitz, Michael Fatis, Samantha Granger, Dane Block, Matthew S. Duarte-García, Alí Warrington, Kenneth J. Theel, Elitza S. Zhou, Xian Zeng, Hu Specks, Ulrich Escalante, Patricio Peikert, Tobias Front Immunol Immunology Humoral vaccine responses are known to be suboptimal in patients receiving B-cell targeted therapy, and little is known about vaccine induced T-cell immunity in these patients. In this study, we characterized humoral and cellular antigen-specific anti-SARS-CoV2 responses following COVID-19 vaccination in patients with ANCA-associated vasculitis (AAV) receiving anti-CD20 therapy, who were either B-cell depleted, or B-cell recovered at the time of vaccination and in normal control subjects. SARS-CoV-2 anti-spike (S) and anti-nucleocapsid (NC) antibodies were measured using electrochemiluminescence immunoassays, while SARS-CoV-2 specific T-cell responses to S glycoprotein subunits 1 (S1) and 2 (S2) and receptor binding domain peptide pools were measured using interferon-gamma enzyme-linked immunosorbent spot (ELISPOT) assays. In total, 26 recently vaccinated subjects were studied. Despite the lack of a measurable humoral immune response, B-cell depleted patients mounted a similar vaccine induced antigen-specific T-cell response compared to B-cell recovered patients and normal controls. Our data indicate that to assure a humoral response in patients receiving anti-CD20 therapy, SARS-CoV-2 vaccination should ideally be delayed until B-cell recovery (CD-20 positive B-cells > 10/μl). Nevertheless, SARS-CoV-2 vaccination elicits robust, potentially protective cellular immune responses in these subjects. Further research to characterize the durability and protective effect of vaccine-induced anti-SARS-CoV-2 specific T-cell immunity are needed. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8831839/ /pubmed/35154159 http://dx.doi.org/10.3389/fimmu.2022.834981 Text en Copyright © 2022 Marty, Van Keulen, Erskine, Shah, Hummel, Stachowitz, Fatis, Granger, Block, Duarte-García, Warrington, Theel, Zhou, Zeng, Specks, Escalante and Peikert https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Marty, Paige K. Van Keulen, Virginia P. Erskine, Courtney L. Shah, Maleeha Hummel, Amber Stachowitz, Michael Fatis, Samantha Granger, Dane Block, Matthew S. Duarte-García, Alí Warrington, Kenneth J. Theel, Elitza S. Zhou, Xian Zeng, Hu Specks, Ulrich Escalante, Patricio Peikert, Tobias Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy |
title | Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy |
title_full | Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy |
title_fullStr | Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy |
title_full_unstemmed | Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy |
title_short | Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy |
title_sort | antigen specific humoral and cellular immunity following sars-cov-2 vaccination in anca-associated vasculitis patients receiving b-cell depleting therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831839/ https://www.ncbi.nlm.nih.gov/pubmed/35154159 http://dx.doi.org/10.3389/fimmu.2022.834981 |
work_keys_str_mv | AT martypaigek antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT vankeulenvirginiap antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT erskinecourtneyl antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT shahmaleeha antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT hummelamber antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT stachowitzmichael antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT fatissamantha antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT grangerdane antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT blockmatthews antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT duartegarciaali antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT warringtonkennethj antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT theelelitzas antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT zhouxian antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT zenghu antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT specksulrich antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT escalantepatricio antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy AT peikerttobias antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy |